Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
70% of patients with Graves disease have elevated anti-TPO antibodies (Lanzolla et al
Both share a cyclic heptapeptide architecture but differ in receptor selectivity, clinical indication (EPP/HSDD vs
Ulschmid, Hans-Michael Mller, Jos Botella-Munoz, Stephan Schneuwly, R
The buyer is comparing a research material, a sample-specific report, bundle costs, and seller terms
doi: 10.1016/j.jclinepi.2010.03.016 27 ChaimaniAHigginsJPMavridisDSpyridonosPSalantiG
US$ 27.51
US$ 22.74
US$ 20.03
US$ 25.63
